Vanda Pharmaceuticals Inc. (VNDA) · Oct 28, 2026 · Earnings
Beat — Diluted EPS loss of $0.37 vs roughly $0.68–$0.72 expected; revenue $69.8M vs ~$69.2M consensus
Vanda earnings beat on revenue growth, Fanapt momentum and lower quarterly losses, though HETLIOZ timing and ongoing cash burn temper the read.
Vanda is shifting from a development-heavy biotech toward a broader commercial portfolio, with Fanapt driving growth, NEREUS newly launched, BYSANTI preparing for launch, and Quimilza awaiting an FDA decision. Its pipeline also targets additional indications for NEREUS and HETLIOZ.
The quarter beat the published earnings bar by a wide margin. Diluted loss was $0.37 per share versus a published consensus of roughly $0.68–$0.72, while revenue of $69.8 million modestly exceeded consensus near $69.2 million. Revenue rose 24% year over year to $69.8 million, while the net loss was essentially flat year over year at $22.6 million.
| Metric | Q3 2026 | Q3 2025 / consensus | Read |
|---|---|---|---|
| Total revenue | $69.8M | $56.3M / ~$69.2M consensus | Revenue beat; +24% year over year |
| Diluted EPS | $(0.37) | $(0.38) / roughly $(0.68)–$(0.72) consensus | Clear EPS beat |
| Net loss | $(22.6)M | $(22.6)M | Flat year over year |
| Operating expenses | $93.3M | $87.5M year ago | Still elevated, but down sequentially |
| Cash and marketable securities | $140.5M | $263.8M at December 31, 2025 | Liquidity materially lower year to date |
Fanapt is the cleanest evidence that the commercial buildout is working. Fanapt sales increased 24% year over year to $38.8 million, and prescriptions rose 25%, with new-to-brand prescriptions up 18%. 〔0〕 That is more durable than the headline revenue growth because it reflects underlying demand rather than a one-time shipment timing effect.
The revenue beat is somewhat less clean because HETLIOZ included a $7 million timing benefit. The company recognized orders shipped on June 29 but received on July 1 in the third quarter, lifting HETLIOZ revenue to $21.7 million. NEREUS contributed $1.6 million, up 60% from the second quarter, but it remains too small to materially change the overall earnings profile.
The cost structure is beginning to turn, but financing pressure has not disappeared. Operating expenses fell 18% from the second quarter as major trial and launch-preparation work concluded, and the quarterly operating loss improved to $23.5 million from $31.3 million a year earlier. 〔1〕 However, nine-month net loss widened to $133.6 million from $79.3 million, while cash plus marketable securities fell to $140.5 million from $263.8 million at year-end. That leaves the business dependent on continued product growth, expense reductions and upcoming launches rather than current profitability.
The next value inflection points are regulatory and launch execution, not this quarter’s income statement. BYSANTI is expected to launch in Q4 2026, Quimilza has a December 12 FDA action date, and the company plans to pursue additional indications for NEREUS and HETLIOZ. 〔2〕 The filing excerpt references a 2026 financial-guidance section but does not provide the guidance figures, so there is no basis here to judge whether the full-year outlook was raised, reaffirmed or cut.
Bottom line: This was a genuine earnings beat, supported by strong Fanapt demand and early NEREUS growth, with expenses starting to normalize. The improvement matters, but the broader story still hinges on BYSANTI’s launch, Quimilza’s FDA decision and whether cash burn continues to fall.
Quimilza FDA decision, December 12, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!